WGS GeneDx Holdings Corp.
USHealthcareAs of 2026-07-08 16:00
Why WGS matters now
GeneDx Holdings Corp. (WGS) is a US stock in Healthcare. The latest InvestLog snapshot shows $65.62 with +0.31% on the session and $1.95B in market capitalization; recent performance reads 1-month +40.07% and YTD -54.63%.
The latest financial table shown here is Q1 2026, with revenue of $102.3M, net income of $-63.3M, and EPS of $-2.16. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -1.6%.
The latest indexable market news headline is "ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages GeneDx Holdings Corp. Investors to Secure Counsel Before Important Deadline in Securities Class Action - WGS" from Globe News Wire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $85.00; recent insider activity includes Stueland Katherine filing M-Exempt. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
6.81
P/S
3.96
EV/EBITDA
-37.65
DCF Value
$-175.77
FCF Yield
-1.6%
Div Yield
0.0%
Margins & Returns
Gross Margin
68.3%
Operating Margin
-7.7%
Net Margin
-17.6%
ROE
-27.5%
ROA
-15.4%
ROIC
-8.1%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $102.3M | $-63.3M | $-2.16 |
| Q4 2025 | $121.0M | $-17.7M | $-0.59 |
| FY 2025 | $427.5M | $-21.0M | $-0.73 |
| Q3 2025 | $116.7M | $-7.6M | $-0.27 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$96.43
Target (Median)
$85.00
Target Range
$70.00 - $150.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Medical - Healthcare Information Services
Country
US
Exchange
—
Beta
1.97
GeneDx Holdings Corp. functions as a health intelligence firm singularly focused on the individual patient. It aims to revolutionize healthcare delivery by deploying advanced artificial intelligence and machine learning capabilities. These sophisticated algorithms are applied to vast, longitudinal clinical and genomic datasets to construct comprehensive, dynamic models of human health, ultimately defining personalized, optimal pathways for each person's well-being. Through its exclusive Centrellis health intelligence platform, the company gains profound insights into both disease states and overall wellness, enabling it to furnish evidence-based solutions for the most critical medical challenges. Eric Schadt established the corporation in October 2015, and its principal offices are located in Stamford, Connecticut.